Ximeclav is a combination antibiotic containing Cefuroxime Axetil, a second-generation cephalosporin, and Clavulanic Acid, a beta-lactamase inhibitor. This formulation effectively treats various bacterial infections by inhibiting bacterial cell wall synthesis and protecting the antibiotic from degradation by beta-lactamase enzymes.